Abstracts tagged "DMARDs"

Abstract Number: 423 • 2014 ACR/ARHP Annual Meeting
Circulating Anti-Citrullinated Peptide Antibodies and Cytokines As Biomarkers of Response to Disease-Modifying Antirheumatic Drugs Therapy in Early Rheumatoid Arthritis
Mahmood MTM Ally¹, Pieter Meyer², Bridget Hodkinson³, Eustasius Musenge⁴, Gregory Tintinger², Mohammed Tikly⁵ and Ronald Anderson¹, ¹University of Pretoria, Pretoria, South Africa, ²university of pretoria, pretoria, South Africa, ³Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, ⁴University of Witwatersrand, Johannesburg, South Africa, ⁵Rheumatology Wits University, C H Baragwanath Hospital, Johannesburg, South Africa
Background/Purpose Serial measurement of circulating anti-citrullinated peptide antibodies (ACPA) and cytokines is of potential importance in the management of patients with rheumatoid arthritis (RA). However,…
Abstract Number: 2810 • 2014 ACR/ARHP Annual Meeting
Reduced Mortality Risk in Rheumatoid Arthritis: Findings from Two UK Inception Cohorts
Sam Norton¹, Elena Nikiphorou², Lewis Carpenter³, David Walsh^4,5, Patrick Kiely⁶, Josh Dixey⁷ and Adam Young^2,8, ¹Institute of Psychiatry, King's College London, London, United Kingdom, ²School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ³Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ⁴Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, ⁵Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom, ⁶Rheumatology Dept, St. Georges Healthcare NHS Trust, London, United Kingdom, ⁷Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose Rheumatoid arthritis (RA) is associated with a 20 to 30% increased risk of mortality from all-causes compared to the general population. The aim of…
Abstract Number: 1497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Iguratimod for Rheumatoid Arthritis
Tsuneo Kondo¹, Akiko Shibata¹, Ryota Sakai¹, Kentaro Chino¹, Ayumi Okuyama¹, Hirofumi Takei¹ and Koichi Amano², ¹Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, ²Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…
Abstract Number: 301 • 2014 ACR/ARHP Annual Meeting
Pregnancies in Females with Juvenile Idiopathic Arthritis (JIA) Who Were Exposed to Biologics and/or Methotrexate – Results from a Biologic Register
Katrin Stüdemann¹, Martina Niewerth¹, Jens Klotsche¹, Angela Zink², Gerd Horneff³ and Kirsten Minden^1,4, ¹Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Chidlrens´ hospital, Charité University Medicine, Berlin, Germany
Background/Purpose JIA often continues into adult life and affects about 1 in 1,000 people of childbearing age. Little is known about the impact of JIA…
Abstract Number: 2555 • 2014 ACR/ARHP Annual Meeting
The Effect of Co-Medication with Conventional Synthetic (cs)Dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS)– Analysis from the Czech Biologics Registry Attra
Karel Pavelka¹, Jakub Zavada², Marketa Fojtikova³, Sarka Forejtova⁴ and Karel Hejduk⁵, ¹Institute of Rheumatology, Prague, Czech Republic, ²Charles University, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁵Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
Background/Purpose : The role of combined treatment with csDMARDs and anti-TNF therapy in AS is not well established. Methods: Main goal of this study was…
Abstract Number: 1489 • 2014 ACR/ARHP Annual Meeting
Influences of Disease Activity at the Initiation of Iguratimod, a Small Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis –a Multicenter Registry Study-
Yuji Hirano¹, Toshihisa Kojima², Yasuhide Kanayama³, Shinya Hirabara¹, Nobunori Takahashi², Atsushi Kaneko⁴ and Naoki Ishiguro², ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan
Background/Purpose: Iguratimod (IGU), known as T-614, is a small-molecule antirheumatic drug developed in Japan and used in Japanese clinical practice since June in 2012. IGU…
Abstract Number: 274 • 2014 ACR/ARHP Annual Meeting
Treatment Prescribing Patterns in a Cohort of Patients with Juvenile Idiopathic Arthritis (JIA). Data from the Childhood Arthritis Prospective Study
Rebecca Davies¹, Roberto Carrasco², Helen Foster³, Eileen Baildam⁴, Alice Chieng⁵, Joyce Davidson⁶, Yiannis Ioannou⁷, Lucy R. Wedderburn⁸, Wendy Thomson⁹, Kimme L. Hyrich¹⁰ and on Behalf Of Childhood Arthritis Prospective Study (CAPS)¹¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Newcastle University, Newcastle, United Kingdom, ⁴Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁵Manchester Children's Hospital, Manchester, United Kingdom, ⁶Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁷Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁹Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ¹⁰Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹¹university of Manchester, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a heterogenous disease, classified according to the International League of Associations for Rheumatology (ILAR). Initial treatment is based largely…
Abstract Number: 2565 • 2014 ACR/ARHP Annual Meeting
The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis
Michael J. Nissen¹, Adrian Ciurea², Juerg Bernhard³, Rudiger Muller⁴, Giorgio Tamborrini⁵, Martin Toniolo⁶, Cem Gabay⁷ and Axel Finckh¹, ¹Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²Gloriastrasse 25, Rheumaklinik, Universitatsspital Zurich, Zurich, Switzerland, ³Rheumatology, Solothurn Hospital, Solothurn, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland, ⁶Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁷University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland
Background/Purpose: Randomized clinical trials and current recommendations suggest little role for disease-modifying anti-rheumatic drugs (DMARDs) as co-therapy with anti-TNF (aTNF) agents in patients with axial-spondyloarthritis…
Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting
Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting
Yomei Shaw¹, Chung-Chou H. Chang², Marc C. Levesque³, Julie M. Donohue⁴, Kaleb Michaud^5,6 and Mark S. Roberts¹, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ⁴Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS, ⁶Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…
Abstract Number: L2 • 2014 ACR/ARHP Annual Meeting
A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study
Petra C.E. Hissink Muller^1,2, D.M.C. Brinkman^1,3, Dieneke Schonenberg⁴, Yvonne Koopman-Keemink⁵, J. Merlijn Van den Berg⁶, W.P. Bekkering⁷, Marion van Rossum^8,9, Lisette WA van Suijlekom-Smit¹⁰, Cornelia F. Allaart¹¹ and Rebecca ten Cate¹, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pediatric Rheumatology, Reade, Amsterdam, Netherlands, ³Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, ⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁵Pediatrics, Haga ziekenhuis, The Hague, Netherlands, ⁶Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁷Pediatric Physiotherapy, Leiden University Medical Center, Leiden, Netherlands, ⁸Pediatric Rheumatology Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁹Reade, Amsterdam, Netherlands, ¹⁰Pediatric Rheumatology, Sophia Children's Hospital Erasmus Medical Center, Rotterdam, Netherlands, ¹¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: BeSt for Kids compares 3 Disease Modifying Anti Rheumatic Drug (DMARD) strategies in juvenile idiopathic arthritis (JIA) patients, for time to inactive disease, time…
Abstract Number: 2552 • 2014 ACR/ARHP Annual Meeting
Effectiveness and Safety of Low-Dose Cyclosporine a in Patients with Primary Sjögren’s Syndrome (pSS) with Articular Involvement – Results of a Pilot Study
Claudia Kedor¹, Jan Zernicke¹, Anja Hagemann², Kathrin Mattat¹, Gerd Burmester¹ and Eugen Feist¹, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Department of Rheumatology and Immunology, Charité University Medicine, Berlin, Germany
Background/Purpose Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease, where musculoskeletal manifestations are usually treated by symptomatic measures and different conventional DMARDs by off-label…
Abstract Number: 1435 • 2014 ACR/ARHP Annual Meeting
Changes in the Types and Prognoses of Infections Complicated in RA Patients during the Last 15 Years, in Japan.
Yoichiro Akiyama¹, Takeo Sato¹, Takamasa Murosaki¹, Katsuya Nagatani¹ and Seiji Minota², ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ²Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi-Ken, Japan
[Background/Purpose ] Infliximab was introduced in 2002 as the first biological DMARD (bDMARD) in Japan. Currently, 5 TNF inhibitors, tocilizumab, and abatacept are available. Tacrolimus…
Abstract Number: 2520 • 2014 ACR/ARHP Annual Meeting
Patient, Genetic and Disease Factors Influence the Response to the Disease Modifying Anti-Rheumatic Drug Leflunomide
Michael D. Wiese¹, Ashley Hopkins², Llew Spargo³, Leah McWilliams³, Catherine O'Doherty², Leslie G. Cleland³ and Susanna Proudman⁴, ¹Division of Health Sciences, School of Pharmacy, University of South Australia, Adelaide, Australia, ²School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ³Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁴Department of Rheumatology, Royal Adelaide Hospital, SA, Australia
Background/Purpose . Leflunomide is a disease modifying anti-rheumatic drug that is used in the treatment of rheumatoid arthritis (RA). Leflunomide is converted to teriflunomide by the…
Abstract Number: 1358 • 2014 ACR/ARHP Annual Meeting
A Systematic Analysis of the Safety of Prescribing Anti-Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women
Sonia Panchal¹, Julia Flint², Maud van de Venne³, Madeline Piper⁴, Alice Hurrel⁵, Joel Cunningham⁵, Mary Gayed⁶, Karen Schreiber⁷, Subha Anthanari⁸, Mohamed Nisar⁸, David Williams⁹, Munther Khamashta¹⁰, Caroline Gordon¹¹ and Ian Giles², ¹Rheumatology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom, ²UCL Division of Medicine, University College London, London, United Kingdom, ³Obstetrics and Gynaecology, North Bristol NHS Trust, Bristol, United Kingdom, ⁴Ysbyty Ystrad Fawr, Aneurin Bevan Health Board Wales, Wales, United Kingdom, ⁵Institute for Women's Health, University College London, London, United Kingdom, ⁶Rheumatology Division of Infection and Immunity, The Medical School, University of Birmingham, Birmingham, United Kingdom, ⁷Lupus Research Unit, Division of Infection and Immunity, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁸Rheumatology, Burton Hospitals NHS Foundation Trust, Burton-upon-Trent, United Kingdom, ⁹University College London, London, United Kingdom, ¹⁰Lupus Research Unit, Division of Women's Health, Guy's and St Thomas' NSH Foundation Trust, London, United Kingdom, ¹¹Rheumatology, Division of Infection and Immunity, The Medical School, University of Birmingham, Birmingham, United Kingdom
Background/Purpose The use of anti-rheumatic drugs in pregnancy is often complicated by concerns over their potential for adverse effects. Given that rheumatic diseases often affect…
Abstract Number: 2525 • 2014 ACR/ARHP Annual Meeting
Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial
Jonas K Eriksson¹, Heather Miller², Johan A Karlsson³, Ingemar F Petersson⁴, Sofia Ernestam⁵, Pierre Geborek³, Ronald F van Vollenhoven² and Martin Neovius¹, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁴Section of Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Department of Learning, Informatics and Medical Education (LIME), Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The introduction of TNF inhibitors has improved the treatment of RA, but at a substantial cost. The randomized Swefot trial compared the addition of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].